The Future is Bright – Clinical Data and New Technology

Hosted by Nancy Hanna and
Dena Gottesman

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In the inaugural episode of Beyond the Bolus, recorded live from the 82nd American Diabetes Association Conference, Nancy and Dena meet with Endocrinologists Dr. Grazia Aleppo and Dr. Amy Criego to discuss ADA highlights and understand how technology advancements are translating into day-to-day wins for people with diabetes. They discuss NEW extension data from the Omnipod® 5 Automated Insulin Delivery System and their clinical pearls and real-world experience with Omnipod 5 during the pivotal trial and extension. They share the challenges and wins for both the adult and pediatric populations and the tremendous impact that technology can have in simplifying life for people with diabetes.

Time stamps

8:43 – Hear how diabetes technology is advancing and how that translates to more options for patients
16:00 – What are patients looking for when they choose an AID system?
21:41 – Find out what surprised Dr. Aleppo and Dr. Criego during the pivotal and extension trials

 

See more episodes
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.